Literature DB >> 23624155

Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done?

David W C Beasley1, Alan D T Barrett, Robert B Tesh.   

Abstract

The resurgence in cases of neurologic disease caused by West Nile virus (WNV) in the United States in 2012 came as a surprise to the general public and to many non-arbovirus researchers. Following the introduction of WNV into the US in 1999, the number of human infections rose dramatically, peaking in 2002-03. However, cases declined from 2008-11, and it was unclear if the virus would continue to have a low-level endemic transmission pattern with occasional outbreaks, like the related flavivirus, Saint Louis encephalitis virus, or a more active pattern with annual outbreaks, including occasional years with large epidemics, like Japanese encephalitis virus. The large epidemic in 2012 suggests that the United States can expect periodic outbreaks of West Nile fever and neurologic disease in the coming years. In this paper, we consider the causes of the upsurge in WNV infections during the past year and their implications for future research and disease control measures.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23624155     DOI: 10.1016/j.antiviral.2013.04.015

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  33 in total

1.  Culex Flavivirus During West Nile Virus Epidemic and Interepidemic Years in Chicago, United States.

Authors:  Christina M Newman; Bethany L Krebs; Tavis K Anderson; Gabriel L Hamer; Marilyn O Ruiz; Jeffrey D Brawn; William M Brown; Uriel D Kitron; Tony L Goldberg
Journal:  Vector Borne Zoonotic Dis       Date:  2017-06-19       Impact factor: 2.133

2.  Integrated analysis of microRNAs and their disease related targets in the brain of mice infected with West Nile virus.

Authors:  Mukesh Kumar; Vivek R Nerurkar
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

Review 3.  Neuroinvasive arboviral disease in the United States: 2003 to 2012.

Authors:  James T Gaensbauer; Nicole P Lindsey; Kevin Messacar; J Erin Staples; Marc Fischer
Journal:  Pediatrics       Date:  2014-08-11       Impact factor: 7.124

Review 4.  A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

5.  Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.

Authors:  Jacob Nelson; Kelsey Roe; Beverly Orillo; Pei-Yong Shi; Saguna Verma
Journal:  Antiviral Res       Date:  2015-07-29       Impact factor: 5.970

6.  In Vitro and In Vivo Blood-Brain Barrier Models to Study West Nile Virus Pathogenesis.

Authors:  Mukesh Kumar; Vivek R Nerurkar
Journal:  Methods Mol Biol       Date:  2016

7.  Extrinsic Incubation Rate is Not Accelerated in Recent California Strains of West Nile Virus in Culex tarsalis (Diptera: Culicidae).

Authors:  Mary E Danforth; William K Reisen; Christopher M Barker
Journal:  J Med Entomol       Date:  2015-07-02       Impact factor: 2.278

8.  Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Authors:  Swati Mukherjee; Kimberly A Dowd; Carolyn J Manhart; Julie E Ledgerwood; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

9.  The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Authors:  Phong D Lee; Swati Mukherjee; Melissa A Edeling; Kimberly A Dowd; S Kyle Austin; Carolyn J Manhart; Michael S Diamond; Daved H Fremont; Theodore C Pierson
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

Review 10.  Current developments in understanding of West Nile virus central nervous system disease.

Authors:  Kenneth L Tyler
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.